Safety and efficacy of adjuvants in vitrectomy

Safety and efficacy of adjuvants in vitrectomy for macular hole

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs021200022

Enrollment

Registered

2020-10-01

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular hole

Interventions

Vitrectomy with internal limiting membrane peeling using BBG, ICG and TA as surgical adjuvants

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases with macular hole

Exclusion criteria

Exclusion criteria: Cases who have vitrectomy and whose axial length is more than 27mm

Design outcomes

Primary

Measure	Time frame
Displacement distance of retinal vessel determined by OCT angiography	—

Secondary

Measure	Time frame
Association of macular displacement with changes in function determined by anorthopia and visual acuity, and morphology determined by retinal and choroidal thickness	—

Contacts

Public ContactTakeshi Iwase

Akita University Hospital

tiwase@med.akita-u.ac.jp+81-188846167

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026